Notable Analyst Rating Changes 01/29: (GSK) (HOV) (ERIC) Upgraded; (VMW) (MGM) (FTNT) Downgraded

January 29, 2013 10:57 AM EST Send to a Friend
UPGRADES
Barclays upgrades GlaxoSmithKline (NYSE: GSK) from Equalweight to Overweight.

Compass Point boosts Hovnanian Enterprises (NYSE: HOV) from Sell to Neutral, moving its price target from $3.50 up to $5.50. Click Here for more color.

Deutsche Bank raises Ericsson (Nasdaq: ERIC) from Hold to Buy and raises its price target from SEK61 to SEK80. Click Here for more color.

BofA/Merrill Lynch lifts Tyson (NYSE: TSN) from Underperform to Buy.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
VMware (NYSE: VMW) downgraded by a handful Tuesday:
  • Topeka Capital from Buy to Hold, adjusting its price target from $120 down to $84. Click Here for more color;

  • Wunderlich Securities from Buy to Hold, moving its price target from $100 down to $75;

  • Goldman Sachs removes from its Conviction Buy List, maintaining a Buy, while adjusting its price target from $130 down to $100. Click Here for more color;

  • Sterne Agee from Buy to Neutral, lowering its price target from $103 to $86; and

  • Piper Jaffray from Overweight to Neutral with a price target of $90.

Deutsche Bank lowers MGM Resorts (NYSE: MGM) from Buy to Hold with a price target of $13. Click Here for more color.

Wunderlich Securities trims Fortinet (Nasdaq: FTNT) from Buy to Hold, moving its price target from $28 down to $22.

Wedbush lowers Pandora (NYSE: P) from Outperform to Neutral, while boosting its price target from $10 to $11.50. Click Here for more color.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
Oppenheimer initiates Laboratory Corporation of America (NYSE: LH) with a Perform. Click Here for more color.

Imperial Capital restarts Bonanza Creek Energy (NYSE: BCEI) at In-Line and price target of $33. Click Here for more color.

JPMorgan begins Seadrill Ltd. (NYSE: SDRL) with a Overweight and NOK290 price target.

Oppenheimer assumes Quest Diagnostics (NYSE: DGX) at Underperform and $53 price target. Click Here for more color.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Goldman Sachs Conviction Buy List, Piper Jaffray, Deutsche Bank, JPMorgan, Merrill Lynch, Bank of America, Sterne Agee, Barclays, Notable Analyst Rating Changes, Wunderlich Securities

Add Your Comment